Microbix QAPs to Support Molecular & Antigen Test Platforms for Multiple Diseases...
Usage of QAPs to Validate Whole Workflow Quality Control of Testing...
Record Q2 Sales of $4.9 million, Q2 Net Earnings of $0.7 million...
QAPs Supporting Molecular Diagnostic Tests for Dominant COVID-variant...
Healthcare Investor Conference in Toronto on May 2 & 3, 2022...
QAPs Supporting Tests That Simultaneously Detect Multiple Respiratory Viruses...
QAPs Supporting Screening-Tests for High-Risk Human Papilloma Viruses...
MISSISSAUGA, CANADA, March 31, 2022 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and...
Venerable Business Publication Focusing Exclusively on MicroCap Companies Resumes Publication in Digital Format LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, a global multimedia financial...
Using Shareholder-Approved Plan to Incentivize and Retain...